BusinessAxsome Therapeutics Announces AXS-05 Poster Presentation at the 2018 Annual Meeting of the American Psychiatric AssociationBy Nasdaq OMXMay 3, 2018, 11:02 AM UTC
BusinessSpinogenix Awarded NIH Grant to Develop Novel Neurorestorative Therapeutics for Alzheimer’s DiseaseBy Nasdaq OMXMay 1, 2018, 6:23 PM UTC
BusinessIndia Globalization: The Best of Both Worlds Approach -- CFN MediaBy Nasdaq OMXMay 1, 2018, 12:48 PM UTC
BusinessAxsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine DependenceBy Nasdaq OMXApr 24, 2018, 11:01 AM UTC
BusinessHealth Point Productions' Gene Wilder Bio-Documentary Moving ForwardBy Nasdaq OMXApr 18, 2018, 9:25 PM UTC
BusinessAxsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine DependenceBy Nasdaq OMXMar 27, 2018, 11:00 AM UTC
BusinessCognition Therapeutics Presenting Evidence for Elayta Synaptic Protection in Alzheimer’s Patients at Combined AAT-AD/PD Focus MeetingBy Nasdaq OMXMar 14, 2018, 2:33 PM UTC
BusinessInside Science: Alzheimer's Drug Trials Keep Failing -- It May Be Because We Don't Understand the DiseaseBy Nasdaq OMXMar 13, 2018, 8:29 PM UTC
